Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/174175
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | A new quinoline BRD4 inhibitor targets a distinct latent HIV-1 reservoir for reactivation from other “shock” drugs |
Autor: | Abner, Erik CSIC ORCID; Stoszko, Mateusz; Zeng, Lei; Chen, Heng-Chang; Izquierdo-Bouldstridge, Andrea CSIC ORCID; Konuma, Tsuyoshi; Zorita, Eduard; Fanunza, Elisa; Zhang, Qiang; Mahmoudi, Tokameh; Zhou, Ming-Ming; Filion, Guillaume J.; Jordan, Albert CSIC ORCID | Palabras clave: | BETi BRD4 HIV latency LRAs |
Fecha de publicación: | may-2018 | Editor: | American Society for Microbiology | Citación: | Journal of Virology 92(10): e02056-17 (2018) | Resumen: | Upon HIV-1 infection, a reservoir of latently infected resting T cells prevents the eradication of the virus from patients. To achieve complete depletion, the existing virus-suppressing antiretroviral therapy must be combined with drugs that reactivate the dormant viruses. We previously described a novel chemical scaffold compound, MMQO (8-methoxy-6-methylquinolin-4-ol), that is able to reactivate viral transcription in several models of HIV latency, including J-Lat cells, through an unknown mechanism. MMQO potentiates the activity of known latency-reversing agents (LRAs) or “shock” drugs, such as protein kinase C (PKC) agonists or histone deacetylase (HDAC) inhibitors. Here, we demonstrate that MMQO activates HIV-1 independently of the Tat transactivator. Gene expression microarrays in Jurkat cells indicated that MMQO treatment results in robust immunosuppression, diminishes expression of c-Myc, and causes the dysregulation of acetylation-sensitive genes. These hallmarks indicated that MMQO mimics acetylated lysines of core histones and might function as a bromodomain and extraterminal domain protein family inhibitor (BETi). MMQO functionally mimics the effects of JQ1, a well-known BETi. We confirmed that MMQO interacts with the BET family protein BRD4. Utilizing MMQO and JQ1, we demonstrate how the inhibition of BRD4 targets a subset of latently integrated barcoded proviruses distinct from those targeted by HDAC inhibitors or PKC pathway agonists. Thus, the quinoline-based compound MMQO represents a new class of BET bromodomain inhibitors that, due to its minimalistic structure, holds promise for further optimization for increased affinity and specificity for distinct bromodomain family members and could potentially be of use against a variety of diseases, including HIV infection. | Versión del editor: | https://doi.org/10.1128/JVI.02056-17 | URI: | http://hdl.handle.net/10261/174175 | DOI: | 10.1128/JVI.02056-17 | ISSN: | 0022-538X | E-ISSN: | 1098-5514 |
Aparece en las colecciones: | (IBMB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
29
checked on 15-abr-2024
SCOPUSTM
Citations
38
checked on 16-abr-2024
WEB OF SCIENCETM
Citations
38
checked on 25-feb-2024
Page view(s)
274
checked on 19-abr-2024
Download(s)
136
checked on 19-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.